{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:21Z","timestamp":1786980261956,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"INMUNOVA SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Shiga toxin-producing\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      -associated hemolytic uremic syndrome (STEC-HUS) is a severe condition mainly affecting children. It is one of the leading causes of acute kidney injury in the pediatric population. There is no established therapy for this disease. INM004 is an anti-Shiga toxin composed of equine polyclonal antibodies. This study is aimed at assessing the safety, pharmacokinetics, and efficacy of INM004 in pediatric patients with STEC-HUS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Phase 2, open-label clinical trial with an historical control arm. Patients in the treatment arm received two doses of INM004. The primary endpoints were the safety profile, pharmacokinetics, and efficacy (dialysis days) of INM004. Secondary endpoints included other kidney and extrarenal outcomes. Propensity score matching was used for efficacy comparisons between arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-seven and 125 patients were enrolled in the treatment and control arm, respectively. After propensity score matching, 52 patients remained in each arm. INM004 was well-tolerated. Eight adverse events were considered possibly related, none of which were serious or severe. In the primary efficacy endpoint, patients of the treatment arm presented a non-statistically significant difference of two dialysis days. On secondary endpoints, non-statistically significant trends toward fewer patients needing dialysis and dialysis for more than 10\u00a0days, and shorter time to glomerular filtration rate normalization, were observed favoring the treatment arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>INM004 showed an adequate safety profile. Efficacy non-statistically significant trends suggesting a beneficial effect in the amelioration of kidney injury were observed. These results encourage the conduction of a phase 3 study of INM004 in pediatric patients with STEC-HUS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-024-06583-3","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T18:53:12Z","timestamp":1731351192000},"page":"1983-1995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli\u2013associated hemolytic uremic syndrome"],"prefix":"10.1007","volume":"40","author":[{"given":"Alicia","family":"Fayad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iliana","family":"Principi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Balestracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Alconcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Coccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Adragna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Amoreo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carolina","family":"Bettendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Valeria","family":"Blumetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Bonany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Laura Flores","family":"Tonfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Seminara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Spizzirri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Pichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Zylberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Spatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Sanguineti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Colonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Roubicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-3002","authenticated-orcid":false,"given":"Fernando","family":"Goldbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of INM004 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"6583_CR1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.pcl.2022.07.006","volume":"69","author":"O Boyer","year":"2022","unstructured":"Boyer O, Niaudet P (2022) Hemolytic-uremic syndrome in children. Pediatr Clin North Am 69:1181\u20131197. https:\/\/doi.org\/10.1016\/j.pcl.2022.07.006","journal-title":"Pediatr Clin North Am"},{"key":"6583_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fr\u00e9meaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet 390:681\u2013696. https:\/\/doi.org\/10.1016\/S0140-6736(17)30062-4","journal-title":"Lancet"},{"key":"6583_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.medmal.2017.09.012","volume":"48","author":"M Bruyand","year":"2018","unstructured":"Bruyand M, Mariani-Kurkdjian P, Gouali M, de Valk H, Le Hello S, Bonacorsi S, Loirat C (2018) Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect 48:167\u2013174. https:\/\/doi.org\/10.1016\/j.medmal.2017.09.012","journal-title":"Med Mal Infect"},{"key":"6583_CR4","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00467-020-04560-0","volume":"35","author":"E Ylinen","year":"2020","unstructured":"Ylinen E, Salmenlinna S, Halkilahti J, Jahnukainen T, Korhonen L, Virkkala T, Rimhanen-Finne R, Nuutinen M, Kataja J, Arikoski P, Linkosalo L, Bai X, Matussek A, Jalanko H, Sax\u00e9n H (2020) Hemolytic uremic syndrome caused by Shiga toxin\u2013producing Escherichia coli in children: incidence, risk factors, and clinical outcome. Pediatr Nephrol 35:1749\u20131759. https:\/\/doi.org\/10.1007\/s00467-020-04560-0","journal-title":"Pediatr Nephrol"},{"key":"6583_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00467-023-06104-8","volume":"39","author":"A Balestracci","year":"2024","unstructured":"Balestracci A, Meni Battaglia L, Toledo I, Martin SM, Beaudoin L (2024) Duration of prodromal phase and severity of hemolytic uremic syndrome. Pediatr Nephrol 39:213\u2013219. https:\/\/doi.org\/10.1007\/s00467-023-06104-8","journal-title":"Pediatr Nephrol"},{"key":"6583_CR6","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00467-023-06183-7","volume":"39","author":"LF Alconcher","year":"2024","unstructured":"Alconcher LF, Lucarelli LI, Bronfen S, Villarreal F (2024) Kidney sequelae in 281 Shiga toxin\u2013producing Escherichia coli-hemolytic uremic syndrome patients after a median follow-up of 12 years. Pediatr Nephrol 39:1221\u20131228. https:\/\/doi.org\/10.1007\/s00467-023-06183-7","journal-title":"Pediatr Nephrol"},{"key":"6583_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1089\/fpd.2013.1704","volume":"11","author":"SE Majowicz","year":"2014","unstructured":"Majowicz SE, Scallan E, Jones-Bitton A, Sargeant JM, Stapleton J, Angulo FJ, Yeung DH, Kirk MD (2014) Global incidence of human Shiga toxin\u2013producing Escherichia coli infections and deaths: a systematic review and knowledge synthesis. Foodborne Pathog Dis 11:447\u2013455. https:\/\/doi.org\/10.1089\/fpd.2013.1704","journal-title":"Foodborne Pathog Dis"},{"key":"6583_CR8","doi-asserted-by":"publisher","unstructured":"Torti JF, Cuervo P, Nardello A, Pizarro M (2021) Epidemiology and characterization of Shiga toxin-producing Escherichia coli of hemolytic uremic syndrome in Argentina. Cureus. https:\/\/doi.org\/10.7759\/cureus.17213","DOI":"10.7759\/cureus.17213"},{"key":"6583_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.5546\/aap.2021.eng.238","volume":"119","author":"A Balestracci","year":"2021","unstructured":"Balestracci A, Meni Battaglia L, Toledo I, Martin SM, Puyol I, Beaudoin L, Robledo NL (2021) Diagnostic sensitivity of extended renal and hematologic criteria to define hemolytic uremic syndrome. Arch Argent Pediatr 119:238\u2013244. https:\/\/doi.org\/10.5546\/aap.2021.eng.238","journal-title":"Arch Argent Pediatr"},{"key":"6583_CR10","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1128\/AAC.01661-08","volume":"53","author":"M Bitzan","year":"2009","unstructured":"Bitzan M, Poole R, Mehran M, Sicard E, Brockus C, Thuning-Roberson C, Rivi\u00e8re M (2009) Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 53:3081\u20133087. https:\/\/doi.org\/10.1128\/AAC.01661-08","journal-title":"Antimicrob Agents Chemother"},{"key":"6583_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1128\/AAC.00343-09","volume":"54","author":"EL L\u00f3pez","year":"2010","unstructured":"L\u00f3pez EL, Contrini MM, Glatstein E, Gonz\u00e1lez Ayala S, Santoro R, Allende D, Ezcurra G, Teplitz E, Koyama T, Matsumoto Y, Sato H, Sakai K, Hoshide S, Komoriya K, Morita T, Harning R, Brookman S (2010) Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother 54:239\u2013243. https:\/\/doi.org\/10.1128\/AAC.00343-09","journal-title":"Antimicrob Agents Chemother"},{"key":"6583_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1128\/CMR.17.4.926-941.2004","volume":"17","author":"S Tzipori","year":"2004","unstructured":"Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H (2004) Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev 17:926\u2013941. https:\/\/doi.org\/10.1128\/CMR.17.4.926-941.2004","journal-title":"Clin Microbiol Rev"},{"key":"6583_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.36648\/0975-9344.11.3.140","volume":"11","author":"Y Hiriart","year":"2019","unstructured":"Hiriart Y, Pardo B, Bukata L, Lauche C, Mu\u00f1oz L, Berengeno AL, Colonna M, Ortega HH, Goldbaum F, Sanguineti S, Zylverman B (2019) Preclinical studies of NEAST (neutralizing equine anti-Shiga toxin): a potential treatment for prevention of Stec-Hus. Int J Drug Dev Res 11:3. https:\/\/doi.org\/10.36648\/0975-9344.11.3.140","journal-title":"Int J Drug Dev Res"},{"key":"6583_CR14","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.4049\/jimmunol.1300999","volume":"191","author":"MP Mejias","year":"2013","unstructured":"Mejias MP, Ghersi G, Craig PO, Panek CA, Bentancor LV, Baschkier A, Goldbaum FA, Zylberman V, Palermo MS (2013) Immunization with a chimera consisting of the B subunit of Shiga toxin type 2 and Brucella Lumazine synthase confers total protection against Shiga toxins in mice. J Immunol 191:2403\u20132411. https:\/\/doi.org\/10.4049\/jimmunol.1300999","journal-title":"J Immunol"},{"key":"6583_CR15","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/S0140-6736(22)01202-8","volume":"400","author":"M Michael","year":"2022","unstructured":"Michael M, Bagga A, Sartain SE, Smith RJH (2022) Haemolytic uraemic syndrome. Lancet 400:1722\u20131740. https:\/\/doi.org\/10.1016\/S0140-6736(22)01202-8","journal-title":"Lancet"},{"key":"6583_CR16","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/bcp.15999","volume":"90","author":"Y Hiriart","year":"2024","unstructured":"Hiriart Y, Scibona P, Ferraris A, Belloso WH, Beruto V, Bournissen FG, Zylberman V, Mu\u00f1oz L, Goldbaum F, Spatz L, Colonna M, Sanguineti S, Simonovich VA (2024) A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti-Shiga toxin hyperimmune equine F (ab\u2032)2 fragments in healthy volunteers. Br J Clin Pharmacol 90:1142\u20131151. https:\/\/doi.org\/10.1111\/bcp.15999","journal-title":"Br J Clin Pharmacol"},{"key":"6583_CR17","first-page":"27","volume":"34","author":"ML Monteverde","year":"2014","unstructured":"Monteverde ML (2014) S\u00edndrome ur\u00e9mico hemol\u00edtico [Hemolytic uremic syndrome]. Nefrol Di\u00e1lisis Traspl 34:27\u201341","journal-title":"Nefrol Di\u00e1lisis Traspl"},{"key":"6583_CR18","first-page":"59","volume":"9","author":"A Balestracci","year":"2018","unstructured":"Balestracci A, Martin SM, Toledo I et al (2018) S\u00edndrome ur\u00e9mico hemol\u00edtico [Hemolytic uremic syndorme]. Rev Pedi\u00e1trica Elizalde 9:59\u201361","journal-title":"Rev Pedi\u00e1trica Elizalde"},{"key":"6583_CR19","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S0022-3476(76)81125-0","volume":"88","author":"GJ Schwartz","year":"1976","unstructured":"Schwartz GJ, Haycock GB, Chir B, Spitzer A (1976) Plasma creatinine and urea concentration in children: normal values for age and sex. J Pediatr 88:828\u2013830. https:\/\/doi.org\/10.1016\/S0022-3476(76)81125-0","journal-title":"J Pediatr"},{"key":"6583_CR20","doi-asserted-by":"publisher","first-page":"e270422204096","DOI":"10.2174\/2666121702666220427081107","volume":"2","author":"G Santiago","year":"2022","unstructured":"Santiago G, Yanina H, Mu\u00f1oz L, Rey F, Hein G, Sanguineti S, Zylberman V, Ortega H, Marelli B (2022) Development and validation of an ELISA to evaluate neutralizing equine anti Shiga toxin antibodies in preclinical studies. Venoms Toxins 2:e270422204096. https:\/\/doi.org\/10.2174\/2666121702666220427081107","journal-title":"Venoms Toxins"},{"key":"6583_CR21","unstructured":"Shargel L, Yu ABC (2016) Applied biopharmaceutics & pharmacokinetics, Seventh edition. McGraw-Hill Education, New York Chicago San Francisco Athens London Madrid Mexico City Milan New Delhi Singapore Sydney Toronto"},{"key":"6583_CR22","doi-asserted-by":"publisher","first-page":"100843","DOI":"10.1016\/j.eclinm.2021.100843","volume":"34","author":"G Lopardo","year":"2021","unstructured":"Lopardo G, Belloso WH, Nannini E, Colonna M, Sanguineti S, Zylberman V, Mu\u00f1oz L, Dobarro M, Lebersztein G, Farina J, Vidiella G, Bertetti A, Crudo F, Alzogaray MF, Barcelona L, Teijeiro R, Lambert S, Scublinsky D, Iacono M, Stanek V, Solari R, Cruz P, Casas MM, Abusamra L, Luciardi HL, Cremona A, Caruso D, de Miguel B, Perez Lloret S, Mill\u00e1n S, Kilstein Y, Pereiro A, Sued O, Cahn P, Spatz L, Goldbaum F, INM005 Study Group (2021) RBD-specific polyclonal F(ab\u00b4)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: a randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2\/3 clinical trial. EClinicalMedicine 34:100843. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100843","journal-title":"EClinicalMedicine"},{"key":"6583_CR23","doi-asserted-by":"publisher","first-page":"e0274796","DOI":"10.1371\/journal.pone.0274796","volume":"17","author":"DH Farizano Salazar","year":"2022","unstructured":"Farizano Salazar DH, Achinelli F, Colonna M et al (2022) Safety and effectiveness of RBD-specific polyclonal equine F(ab\u00b4)2 fragments for the treatment of hospitalized patients with severe COVID-19 disease: a retrospective cohort study. PLoS One 17:e0274796. https:\/\/doi.org\/10.1371\/journal.pone.0274796","journal-title":"PLoS ONE"},{"key":"6583_CR24","first-page":"107","volume":"78","author":"Y Hiriart","year":"2018","unstructured":"Hiriart Y, Pardo RP, Bukata L, Lauch\u00e9 C, Mu\u00f1oz L, Colonna M, Goldbaum F, Sanguineti S, Zylberman V (2018) Desarrollo de un producto anti-toxina shiga para la prevenci\u00f3n del s\u00edndrome ur\u00e9mico hemol\u00edtico [Development of a product anti-Shiga toxin for prevention of the hemolytic uremic syndrome]. Medicina (B Aires) 78:107\u2013112","journal-title":"Medicina (B Aires)"},{"key":"6583_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s004670050248","volume":"11","author":"FD Spizzirri","year":"1997","unstructured":"Spizzirri FD, Rahman RC, Bibiloni N, Ruscasso JD, Amoreo OR (1997) Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol 11:156\u2013160. https:\/\/doi.org\/10.1007\/s004670050248","journal-title":"Pediatr Nephrol"},{"key":"6583_CR26","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.290.10.1360","volume":"290","author":"AX Garg","year":"2003","unstructured":"Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF (2003) Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 290:1360. https:\/\/doi.org\/10.1001\/jama.290.10.1360","journal-title":"JAMA"},{"key":"6583_CR27","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/cid\/cix218","volume":"64","author":"S Loos","year":"2017","unstructured":"Loos S, Aulbert W, Hoppe B, Ahlenstiel-Grunow T, Kranz B, Wahl C, Staude H, Humberg A, Benz K, Krause M, Pohl M, Liebau MC, Schild R, Lemke J, Beringer O, M\u00fcller D, H\u00e4rtel C, Wigger M, Vester U, Konrad M, Haffner D, Pape L, Oh J, Kemper MJ (2017) Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104:H4. Clin Infect Dis 64:1637\u20131643. https:\/\/doi.org\/10.1093\/cid\/cix218","journal-title":"Clin Infect Dis"},{"key":"6583_CR28","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00467-008-0799-9","volume":"23","author":"RS Oakes","year":"2008","unstructured":"Oakes RS, Kirkhamm JK, Nelson RD, Siegler RL (2008) Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 23:1303\u20131308. https:\/\/doi.org\/10.1007\/s00467-008-0799-9","journal-title":"Pediatr Nephrol"},{"key":"6583_CR29","doi-asserted-by":"publisher","first-page":"e0614","DOI":"10.1097\/CCE.0000000000000614","volume":"4","author":"EH Ulrich","year":"2022","unstructured":"Ulrich EH, Hessey E, Perreault S, Dorais M, Jouvet P, Phan V, Zappitelli M (2022) Association of nonrecovery of kidney function after pediatric acute kidney injury with 5-year kidney and nonkidney outcomes. Crit Care Explor 4:e0614. https:\/\/doi.org\/10.1097\/CCE.0000000000000614","journal-title":"Crit Care Explor"},{"key":"6583_CR30","doi-asserted-by":"publisher","first-page":"205435811988018","DOI":"10.1177\/2054358119880188","volume":"6","author":"E Hessey","year":"2019","unstructured":"Hessey E, Perreault S, Dorais M, Roy L, Zappitelli M (2019) Acute kidney injury in critically ill children and subsequent chronic kidney disease. Can J Kidney Health Dis 6:205435811988018. https:\/\/doi.org\/10.1177\/2054358119880188","journal-title":"Can J Kidney Health Dis"},{"key":"6583_CR31","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1164\/rccm.201604-0799OC","volume":"195","author":"JA Kellum","year":"2017","unstructured":"Kellum JA, Sileanu FE, Bihorac A, Hoste EAJ, Chawla LS (2017) Recovery after acute kidney injury. Am J Respir Crit Care Med 195:784\u2013791. https:\/\/doi.org\/10.1164\/rccm.201604-0799OC","journal-title":"Am J Respir Crit Care Med"},{"key":"6583_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.kint.2018.08.036","volume":"95","author":"EJ See","year":"2019","unstructured":"See EJ, Jayasinghe K, Glassford N, Bailey M, Johnson DW, Polkinghorne KR, Toussaint ND, Bellomo R (2019) Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int 95:160\u2013172. https:\/\/doi.org\/10.1016\/j.kint.2018.08.036","journal-title":"Kidney Int"},{"key":"6583_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1055\/s-2006-939769","volume":"32","author":"D Karpman","year":"2006","unstructured":"Karpman D, Manea M, Vaziri-Sani F, St\u00e5hl A, Kristoffersson A (2006) Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost 32:128\u2013145. https:\/\/doi.org\/10.1055\/s-2006-939769","journal-title":"Semin Thromb Hemost"},{"key":"6583_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/joim.12546","volume":"281","author":"D Karpman","year":"2017","unstructured":"Karpman D, Loos S, Tati R, Arvidsson I (2017) Haemolytic uraemic syndrome. J Intern Med 281:123\u2013148. https:\/\/doi.org\/10.1111\/joim.12546","journal-title":"J Intern Med"},{"key":"6583_CR35","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1160\/TH05-02-0115","volume":"94","author":"F Guessous","year":"2005","unstructured":"Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, Keepers TR, Obrig T, Gear ARL (2005) Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function. Thromb Haemost 94:1019\u20131027. https:\/\/doi.org\/10.1160\/TH05-02-0115","journal-title":"Thromb Haemost"},{"key":"6583_CR36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637. https:\/\/doi.org\/10.1681\/ASN.2008030287","journal-title":"J Am Soc Nephrol"},{"key":"6583_CR37","doi-asserted-by":"publisher","first-page":"793446","DOI":"10.3389\/fped.2021.793446","volume":"9","author":"G-T Chuang","year":"2021","unstructured":"Chuang G-T, Tsai I-J, Tsau Y-K (2021) Serum creatinine reference limits in pediatric population\u2014a single center electronic health record-based database in Taiwan. Front Pediatr 9:793446. https:\/\/doi.org\/10.3389\/fped.2021.793446","journal-title":"Front Pediatr"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06583-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06583-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:55:21Z","timestamp":1745560521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06583-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6583"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06583-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4751636\/v1","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was performed following the principles of the Declaration of Helsinki and Good Clinical Practice. The protocol was approved by the local Ethics Committees of each of the participating centers and the Argentine National Food and Drug Regulatory Agency (ANMAT) after approval by the Ethics Committee accredited by the corresponding Health Authority within the jurisdiction (Disposition Number: DI-2022\u20137068-APN-ANMAT#MS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"AF, IP, AB, LA, PC, MA, OA, MCB, MVB, PB, MLFT, LF, LG, JM, FR, CS, AS, and APS declare reimbursement for conduction of clinical trial as investigator of the study. MR, MP, VZ, LS, CM, MV, SS, MC, IR, and FG report personal fees from Inmunova S.A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}